IMNN

Imunon is a pre-revenue, clinical-stage biotech whose own 10-K states management 'anticipate[s] cash resources will not be sufficient to fund our operations for the next twelve months' and that it 'has no committed sources of additional capital.' That is a textbook going-concern flag, and it is the single most important fact here. With $8.8M of cash against a FY2025 operating cash burn of -$13.9M, the company has well under a year of runway at the current pace. Its stated funding source is issuing stock (ATM program), so the near-certain path is heavy dilution — on a share count that has already been cut 73.2% YoY (a reverse split) to just 3.92M shares, and against $421M of cumulative losses since inception.

The fundamentals offer nothing to offset the balance-sheet risk. There is no meaningful product revenue — the $500K figure is stale FY2022 data, and revenue is shown as '—' for FY2023–FY2025. The P/S of 15.0x is therefore an artifact of a dead revenue line and carries no signal. Net loss was -$14.5M in FY2025 with operating and net margins that are not economically interpretable (roughly -2,900%), and ROE is -205%. R&D fell 33.2% YoY to $7.78M — a cut that helped shrink the loss but is not the sign of a program accelerating toward value; it reads more like resource conservation.